Important #ESMO26 study, published in @Annals_Oncology !
In the phase 3 PERSEE trial adding chemotherapy to pembrolizumab in advanced lung cancer with PD-L1 ≥50% improved median progression-free survival from 6.9 to 16.1 months (HR 0.56).
Median overall survival was 50.2 vs 29.9 months (HR 0.77), although the difference was not statistically significant.
Grade ≥3 treatment-related adverse events increased (54% vs 19%).
An important finding for first-line treatment decisions in PD-L1-high lung cancer.
271 浏览 · 2 赞 · 2 转发 · 1 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSymbiotic-GYN-18 (GOG-3145/ENGOT-EN37/APGOT-EN6/LACOG 0426-EVA): Phase 3 study of PF-08634456 in combination with pembrolizumab versus placebo plus pembrolizumab in participants with advanced or recurrent endometrial cancer
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org- ilyas sahin, MD@ilyassahinMD
https://www.annalsofoncology.org/article/S0923-7534(26)06892-4/fulltext
来源：ilyas sahin, MD · x.com